Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have earned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.9167.

Several analysts recently issued reports on ORIC shares. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. The Goldman Sachs Group upgraded Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Friday, May 15th. Wedbush reduced their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, April 1st. Citigroup cut their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd.

Oric Pharmaceuticals Price Performance

ORIC opened at $9.46 on Friday. The business has a fifty day simple moving average of $8.89 and a 200 day simple moving average of $10.00. The company has a market capitalization of $979.30 million, a PE ratio of -6.57 and a beta of 1.04. Oric Pharmaceuticals has a 1 year low of $7.23 and a 1 year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Equities analysts anticipate that Oric Pharmaceuticals will post -1.45 earnings per share for the current fiscal year.

Institutional Trading of Oric Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Assetmark Inc. bought a new stake in shares of Oric Pharmaceuticals during the 3rd quarter valued at $37,000. Federation des caisses Desjardins du Quebec lifted its position in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after acquiring an additional 2,000 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Oric Pharmaceuticals by 184.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after acquiring an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oric Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after acquiring an additional 977 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in shares of Oric Pharmaceuticals during the 3rd quarter valued at $60,000. 95.05% of the stock is currently owned by institutional investors.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.